EUVIMEDEUVIMED entdecken
Systematische Übersicht

Incretin Dominance and Emerging Mechanisms in Obesity Pharmacotherapy: Insights from 275 Registered Clinical Trials (2019–2024)

Lucas Antônio Dos Santos Barbosa, Bassel Almarie, Eduardo Luiz Gasnhar Moreira

Therapeutic Innovation & Regulatory Science · 2026

DOI: 10.1007/s43441-025-00875-y ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2026. Verfasst von Lucas Antônio Dos Santos Barbosa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Neuroscience, Federal University of Santa Catarina, Florianópolis, SC, Brazil. Hauptthemen laut MEDLINE: Obesity, Incretins, Anti-Obesity Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity remains a critical global health challenge, with rising prevalence and a substantial cardiometabolic and psychosocial burden. Recent therapeutic advances, particularly in incretin-based strategies, underscore the need for a comprehensive characterization of the evolving pharmacological landscape. We conducted a systematic review of clinical trials registered on ClinicalTrials.gov between October 2019 and October 2024, focusing on pharmacological interventions for obesity from early exploratory stages to Phase 3. A total of 275 eligible trials were identified and analyzed. Incretin pathway modulators predominated (69.8%), especially GLP-1 receptor agonists and dual or triple agonists targeting GLP-1, GIP, and glucagon receptors. Most trials were in Phase 2 (40.7%) or Phase 3 (31.3%), indicating a maturing pipeline, while early-stage innovation remained limited (3.3% of trials). Drug repurposing was common (22.2%), notably involving semaglutide and liraglutide, originally approved for type 2 diabetes. Industry-sponsored trials constituted the majority (75.3%), with limited academic (22.2%) and governmental (2.5%) participation. Geographically, trials were concentrated in the United States, China, and Denmark, with relatively few international multicenter studies. While the obesity drug pipeline is expanding rapidly, it remains heavily centered on incretin-based therapies. This dominance, despite strong clinical efficacy, raises concerns regarding long-term safety, accessibility, and mechanistic diversity. Greater investment in early-phase innovation and alternative pharmacological targets will be essential to diversify treatment options and address the unmet need for equitable and sustainable obesity management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityIncretinsAnti-Obesity AgentsHumansClinical Trials as TopicGlucagon-Like Peptide-1 Receptor AgonistsLiraglutide

Stichwörter der Autor:innen

Anti-obesity agentsClinical trialsDrug developmentIncretinsObesity

Substanzen

IncretinsAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsLiraglutide

Autor:innen und Institutionen

  • Graduate Program in Neuroscience, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
  • Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Graduate Program in Neuroscience, Federal University of Santa Catarina, Florianópolis, SC, Brazil. eduardo.luiz@ufsc.br.
  • Department of Physiological Sciences, Federal University of Santa Catarina, Florianopolis, Brazil. eduardo.luiz@ufsc.br.

Zitieren

APA

Dos Santos Barbosa, L. A., Almarie, B., & Moreira, E. L. G. (2026). Incretin Dominance and Emerging Mechanisms in Obesity Pharmacotherapy: Insights from 275 Registered Clinical Trials (2019–2024). Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-025-00875-y

Vancouver

Dos Santos Barbosa LA, Almarie B, Moreira ELG. Incretin Dominance and Emerging Mechanisms in Obesity Pharmacotherapy: Insights from 275 Registered Clinical Trials (2019–2024). Therapeutic Innovation & Regulatory Science. 2026. doi:10.1007/s43441-025-00875-y

BibTeX
@article{DosSantosBarbosa2026,
  author = {Dos Santos Barbosa, Lucas Antônio and Almarie, Bassel and Moreira, Eduardo Luiz Gasnhar},
  title = {Incretin Dominance and Emerging Mechanisms in Obesity Pharmacotherapy: Insights from 275 Registered Clinical Trials (2019–2024)},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  doi = {10.1007/s43441-025-00875-y}
}
Kostenlos starten →